Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish ...

Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis. The posters ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “relatively uneventful” besides an announcement for ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...